search
Back to results

Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation

Primary Purpose

Immunosuppressant Associated Diarrhea

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Probiotic Supplement
Placebo
Sponsored by
Swedish Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Immunosuppressant Associated Diarrhea focused on measuring Renal transplantation, Diarrhea, Immunosuppression, Probiotics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: all subjects aged >/= 18 years who qualify to receive a living (related or unrelated) or cadaveric kidney allograft using steroid free induction immunosuppression. single organ recipient (kidney only) subjects receiving first or second renal transplant women of child-bearing potential should have a negative serum pregnancy test within 1 week prior to beginning study medications subjects with no known contraindications to treatment with any of the study drugs subjects providing written consent subjects who are compliant and able to complete all the necessary assessment procedures Exclusion Criteria: Subjects < 18 years of age Subjects who do not meet criteria for steroid free protocol subjects with known intolerance to lactobacillus subjects with history of chronic diarrhea subjects with history of gastrointestinal disorder that may interfere with their ability to absorb oral medication: inflammatory bowel disease, irritable bowel syndrome, short gut syndrome, or ileo jejunal surgery subjects with known laxative abuse subjects with pancreatic insufficiency subjects who are pregnant, lactating or nursing subjects with active peptic ulcer disease child bearing women not willing to use a reliable form of contraception subjects with prior history of C. difficile subjects receiving other medications considered to be experimental for control of diarrhea

Sites / Locations

  • Swedish Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

I

II

Arm Description

Placebo

Probiotic supplement

Outcomes

Primary Outcome Measures

To maintain normal bowel function and significantly moderate or obviate Immunosuppression Associated Diarrhea following kidney transplantation, utilizing a daily questionnaire, stool cultures and C. Difficile.

Secondary Outcome Measures

Determine the impact of IAD on therapeutic drug levels. Taper or change of immunosuppressive medications due to IAD.

Full Information

First Posted
August 11, 2006
Last Updated
July 22, 2011
Sponsor
Swedish Medical Center
Collaborators
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT00364650
Brief Title
Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation
Official Title
Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation: a Single Center Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2011
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Swedish Medical Center
Collaborators
Hoffmann-La Roche

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
We hypothesize that the administration of a combination of high numbers of probiotic bacteria will maintain normal bowel function and significantly moderate or obviate Immunosuppression Associated Diarrhea following kidney transplantation.
Detailed Description
Immunosuppression following organ transplantation is associated with a myriad of gastrointestinal complications including severe diarrhea. Mycophenolate mofetil (MMF) is the immunosuppressant most often associated with this plaguing symptom. A retrospective study of patients from 10 US transplant centers receiving MMF immunosuppression after kidney transplantation showed that nearly 50% of patients suffered from at least one gastrointestinal symptom within the first 6 months after transplantation. (Tierce 2005) The majority of these patients have diarrhea. However, Immunosuppression Associated Diarrhea (IAD) is often observed in association with other immunosuppressive agents as well. It is the investigator's observation that IAD is equally problematic whether the immunosuppressive regimen includes MMF or not. When IAD is severe it can be difficult for the recipient to maintain adequate levels of immunosuppression. Not infrequently, IAD is so distressing that a recipient's immunosuppressive medications are tapered, changed or stopped. During these times of drug manipulation, patients are at risk for early acute rejection. Approximately 30% of renal transplant patients who have their MMF regimen adjusted or discontinued suffer an episode of acute rejection. Reversing a rejection episode is expensive and adds significant risks for the recipient and long-term allograft survival. Thus, a strategy to support and maintain normal healthy bowel function moderating or obviating IAD is highly desirable. Repopulation of the normal intestinal microflora in kidney transplant patients after kidney transplantation may maintain normal bowel function. This study is designed to test the hypothesis that the administration of a food supplement probiotic consisting of high amounts of six strains of lactic acid bacteria normally found in the human colon will favorably support and maintain bowel function moderating or obviating IAD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Immunosuppressant Associated Diarrhea
Keywords
Renal transplantation, Diarrhea, Immunosuppression, Probiotics

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
I
Arm Type
Placebo Comparator
Arm Description
Placebo
Arm Title
II
Arm Type
Experimental
Arm Description
Probiotic supplement
Intervention Type
Drug
Intervention Name(s)
Probiotic Supplement
Intervention Description
2 capsules twice daily
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
To maintain normal bowel function and significantly moderate or obviate Immunosuppression Associated Diarrhea following kidney transplantation, utilizing a daily questionnaire, stool cultures and C. Difficile.
Time Frame
5 months
Secondary Outcome Measure Information:
Title
Determine the impact of IAD on therapeutic drug levels. Taper or change of immunosuppressive medications due to IAD.
Time Frame
5 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: all subjects aged >/= 18 years who qualify to receive a living (related or unrelated) or cadaveric kidney allograft using steroid free induction immunosuppression. single organ recipient (kidney only) subjects receiving first or second renal transplant women of child-bearing potential should have a negative serum pregnancy test within 1 week prior to beginning study medications subjects with no known contraindications to treatment with any of the study drugs subjects providing written consent subjects who are compliant and able to complete all the necessary assessment procedures Exclusion Criteria: Subjects < 18 years of age Subjects who do not meet criteria for steroid free protocol subjects with known intolerance to lactobacillus subjects with history of chronic diarrhea subjects with history of gastrointestinal disorder that may interfere with their ability to absorb oral medication: inflammatory bowel disease, irritable bowel syndrome, short gut syndrome, or ileo jejunal surgery subjects with known laxative abuse subjects with pancreatic insufficiency subjects who are pregnant, lactating or nursing subjects with active peptic ulcer disease child bearing women not willing to use a reliable form of contraception subjects with prior history of C. difficile subjects receiving other medications considered to be experimental for control of diarrhea
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William H Marks, MD, PhD
Organizational Affiliation
Swedish Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Swedish Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98122
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
36126902
Citation
Cooper TE, Scholes-Robertson N, Craig JC, Hawley CM, Howell M, Johnson DW, Teixeira-Pinto A, Jaure A, Wong G. Synbiotics, prebiotics and probiotics for solid organ transplant recipients. Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
Results Reference
derived

Learn more about this trial

Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation

We'll reach out to this number within 24 hrs